BioCentury | Oct 7, 2013
Company News

Pierre Fabre, Neurolixis deal

...division granted Neurolixis exclusive, worldwide rights to develop and commercialize serotonergic compounds F15599 and befiradol. F15599...
...disease levodopa-induced dyskinesia (PD-LID). The company is pursuing Orphan Drug designation in the U.S. for F15599...
Items per page:
1 - 1 of 1